Hemostasis is a physiological process critical for survival. Meanwhile, thrombosis is
amongst the leading causes of death worldwide, making antithrombotic therapy one of the …

Background Antiplatelet therapy is recommended among patients with established
atherosclerosis. We compared monotherapy with a P2Y 12 inhibitor versus aspirin for …

Platelets are increasingly being recognized for playing roles beyond thrombosis and
hemostasis. Today we know that they mediate inflammation by direct interactions with innate …

Background: Patients with atrial fibrillation (AF) have an increased risk of cognitive decline,
potentially resulting from clinically unrecognized vascular brain lesions. Objectives: This …

Patients with known cardiovascular disease who have not had a recent acute event are
often referred to as having stable coronary artery disease (CAD). The concept of 'stable'CAD …

Background REDUCE-IT was a double-blind trial that randomized 8,179 statin-treated
patients with controlled low-density lipoprotein cholesterol and moderately elevated …

Aims The 10-year risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events in
patients with established ASCVD can be estimated with the Secondary Manifestations of …

Importance Patients with symptomatic lower extremity peripheral artery disease (LE-PAD)
experience an increased risk of major vascular events. There is limited information on what …

Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute
ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their …

One of the earliest and best-recognized elements of atherosclerosis is its close relationship
with circulating LDL (low-density lipoprotein). There is convincing evidence that LDL …